Sanofi: Press Releases, Monday, December 9, 2019
Additional Indications(*)
| Phase 1 (Total : 5) | Phase 2 (Total : 16) | Phase 3 (Total : 24) | Registration (Total : 2) | ||||
| SAR439459 + cemiplimab(**)(1) Advanced Solid Tumors | dupilumab(**)(1) Grass pollen allergy | isatuximab + cemiplimab(**)(1) Relapsing Refractory MM | Dupixent® (**)(1) Asthma 6 – 11 years old | isatuximab Newly Diag. MM Te(8) (GMMG) | Fluzone® QIV HD Influenza vacc. – High dose (EU) | ||
| O | cemiplimab(**)(1) + REGN4018(2)(**) Ovarian Cancer | R | sarilumab(**)(1) Polyarticular JIA(6) | isatuximab + cemiplimab(**)(1) Lymphoma | dupilumab(**)(1) Eosinophilic Esophagitis | isatuximab 2L RRMM (IKEMA) | MenQuadfi TM U.S. 2y+ , EU 1y+ |
| SAR439859 + palbociclib(3) Metastatic Breast Cancer | R | sarilumab(**)(1) Systemic Juvenile Arthritis | isatuximab + atezolizumab(7) mCRC | Dupixent®(**)(1) AD 6 – 11 years old | Aubagio® Relapsing MS – Pediatric | ||
| sutimlimab ImmuneThrombocytopenic Purpura | SAR440340(**)(1) COPD | isatuximab + atezolizumab(7) Solid Tumors | Dupixent®(**)(1) AD 6 months – 5 years old | Lemtrada® RRMS – Pediatric | |||
| SAR443060(4) Multiple sclerosis | dupilumab(**)(1) Peanut Allergy – Pediatric | venglustat Fabry Disease | sarilumab(**)(1) Giant Cell Arteritis | Cerdelga® Gaucher T1, ERT switch Pediatric | |||
| SAR442720(**)(5) + cobimetinib Relapsed Refractory solid tumors | SAR440340(**)(1) Asthma | venglustat Gaucher Type 3 | sarilumab(**)(1) Polymyalgia Rheumatica | Praluent® (**)(1) LDL-C reduction – Pediatric | |||
| R | cemiplimab(**)(1) 2L Basal Cell Carcinoma | venglustat Parkinson’s Disease with an associated GBA mutation | dupilumab(**)(1) COPD | Praluent® (**)(1) LDL-C reduction – HoFH | |||
| isatuximab 1-2L AML / ALL pediatrics | SP0173 Tdap booster US | cemiplimab(**)(1) 1L NSCLC | MenQuadfi TM US / EU 6w+ | ||||
| cemiplimab(**)(1)+ chemotherapy 1L NSCLC | Pediatric pentavalent vaccine Japan | ||||||
| cemiplimab(**)(1) 2L Cervical Cancer | Shan 6 Pediatric hexavalent vaccine | ||||||
| cemiplimab(**)(1) Adjuvant in CSCC | VerorabVax® (VRVg) Purified vero rabies vaccine | ||||||
| fitusiran Hemophilia A and B pediatric | isatuximab 1L Newly Diag. MM Ti(9) (IMROZ) | ||||||
- Developed in collaboration with Regeneron
- Regeneron product for which Sanofi has opt-in rights
- Pfizer product (palbociclib)
- Developed in collaboration with Denali
- Developed in collaboration with Revolution Medicines – cobimetinib is a Genentech product
- Polyarticular JIA = Polyarticular Juvenile Idiopathic Arthritis
- Studies in collaboration with Genentech Inc. (atezolizumab)
- Transplant eligible
- Transplant ineligible
(*) Phase of projects determined by clinicaltrials.gov disclosure timing when relevant
(**) Partnered and/or in collaboration – Sanofi may have limited or shared rights on some of these products
O : Opt-in rights products for which rights have not been exercised yet
R : Registrational Study (other than Phase 3)
COPD = chronic obstructive pulmonary disease; AML = acute myeloïd leukemia; ALL = acute lymphoblastic leukemia; MM = multiple myloma;RRMS = Relapsing / Remitting Multiple Sclerosis